Research Triangle Park-based Entegrion developed the bandage, called Stasilon, which is made of a proprietary weave of glass and bamboo fibers, two materials that promote clotting. Entegrion has received U.S. Food and Drug Administration clearance for Stasilon as a medical device. Now it’s in the hands of Beeken for commercialization. Financial terms of the deal were not disclosed. Beeken CEO Rich Kendall said in an interview that Stasilon is the first of what the company hopes will be many wound care product licensing deals.
“We’re actively looking for other products to add to our portfolio,” he said.
Kendall, a co-founder of Beeken, is based in the Boston area. Fellow co-founder and company Chairman Peter Beemsterboer works from Chicago where Beeken is based. Beeken was founded last September. The Stasilon licensing deal was completed at the beginning of April.
Before starting Beeken, Kendall worked as the vice president of sales and marketing for Entegrion. Beemsterboer owns a company that was handling distribution of Stasilon to non-hospital markets such as physicians offices and clinics. While the product was attracting some sales, Kendall said it became evident that Stasilon needed the financial muscle of a company that could devote resources to its commercialization. Beemsterboer’s mark in the business world is through Beemsterboer Industries, a privately held company whose roots in the coal and steel industries date to the 1920s. More recently, the company has since diversified into other areas including healthcare. Beemsterboer Industries acquired its first healthcare company five years ago with the purchase of diabetes supplies company Horizon MedCorp, based in Winston-Salem, North Carolina.
Kendall said Beeken’s next step is to get Stasilon into hospitals. He said Beeken is also discussing partnerships with several companies that could further broaden the commercial availability of the bandage. The company is building up its sales team and expects to have a formal launch of Stasilon this summer.
Stasilon is the first product from Entegrion, which has a pipeline on blood-based therapies and drug products in development. Entegrion was founded in 2002 and has developed technologies based on intellectual property from both the University of North Carolina at Chapel Hill and East Carolina University.